Translocations or amplifications on top of the genomic alterations previously current in the original CLL, but lack the typical mutations observed in Main DLBCL indicating they could correspond to a special biological classification. This feature can be particularly worthwhile for non-compliant individuals or All those in whom ibrutinib is contraindicated. https://johnc210odr7.wikissl.com/user